How did the FDA got browbeaten into approving an Alzheimer's drug that may not work?
Advertisementthat the funding was based on an application that had been repeatedly rejected by CIRM’s scientific review panel, largely because the reviewing experts considered the data supporting the application less than “compelling.”
As it happens, the company ended the research program in 2014, after spending $8.9 million of its grant and “ With high drug prices still in the political crosshairs on Capitol Hill, pharmaceutical industry bosses are at pains to explain why a cure for hepatitis-C has to cost a budget-busting $1,000 per pill, or a promising cancer treatment should carry a list price of $373,000.
,” neurologist David Knopman of the Mayo Clinic, stated prior to a key panel meeting last Nov. 6. “Four years from now, it is very unlikely that any Alzheimer patient will genuinely be better off as a result of aducanumab — at best slightly less worse, but no better.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Controversial drug approval stokes concern about lack of a permanent FDA chiefThe FDA’s approval of a controversial new Alzheimer’s drug this week has hardened opposition to acting commissioner Janet Woodcock, who remains President Joe Biden’s apparent favorite to be the agency’s permanent leader
Read more »
Johnson & Johnson says FDA has extended shelf life of single-dose COVID vaccine by six weeksOriginal three-month expiration dates loomed at end of June.
Read more »
Two doctors have resigned from a prestigious panel after FDA approved a controversial Alzheimer's drugBusiness Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »
Two members of U.S. FDA advisory panel resign over Alzheimer's drug approvalTwo members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at the agency's decision to approve Biogen Inc's (BIIB.O) Aduhelm for treatment of Alzheimer's disease despite the committee’s recommendation against doing so.
Read more »
Moderna asks FDA to clear Covid vaccine for adolescents 12 to 17If approved, it would likely dramatically expand the number of Covid vaccine shots available to middle and high school students ahead of the next school year.
Read more »